CA
GILD icon

Cynosure Advisors’s Gilead Sciences GILD Stock Holding History

Cynosure Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24,047
Closed -$1.7M – 86
2018
Q2 		$1.7M Buy
24,047
+3,245
+16% +$229K 0.46% 23
2018
Q1 		$1.57M Buy
20,802
+11,892
+133% +$945K 0.4% 23
2017
Q4 		$638K Buy
+8,910
New +$677K 0.15% 77

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cynosure Advisors's GILD Position: Q3 2018 in Review

Cynosure Advisors sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 24,047 shares — an estimated $1.7M sold.

Cynosure Advisors first reported a position in GILD in Q4 2017 and held it in 3 quarters. The position peaked at $1.7M in Q2 2018. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

  • Cynosure Advisors reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
  • Cynosure Advisors sold 24,047 Gilead Sciences shares in Q3 2018, an estimated $1.7M.
  • Cynosure Advisors first reported a position in Gilead Sciences in Q4 2017 and held it in 3 quarters.
  • Cynosure Advisors's Gilead Sciences position peaked at $1.7M in Q2 2018.
  • 1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Cynosure Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.